Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies.
This paper describes the background and current status of an OMERACT facilitated effort to improve the consistency of adverse event reporting in rheumatology clinical trials. The overall goal is the development of an adverse event assessment tool that would provide a basis for use of common terminology and improve the consistency of reporting severity of side effects within rheumatology clinical trials and during postmarketing surveillance. The resulting Rheumatology Common Toxicity Criteria Index encompassed the following organ systems: allergic/immunologic, cardiac, ENT, gastrointestinal, musculoskeletal, neuropsychiatric, ophthalmologic, pulmonary and skin/integument. Before this tool is widely accepted, its validity, consistency, and feasibility need to be assessed in clinical trials.
Woodworth
T G
TG
Pfizer Groton R & D, Groton, CT, USA. thasia_g_woodworth@groton.pfizer.com
Furst
D E
DE
Strand
V
V
Kempeni
J
J
Fenner
H
H
Lau
C S
CS
Miller
F
F
Day
R
R
Lipani
J
J
Brooks
P
P
D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000633:toxicity*; D002986:Clinical Trials as Topic / Q000592:standards*; D006801:Humans; D017410:Practice Guidelines as Topic / Q000592:standards; D012216:Rheumatic Diseases / Q000188:drug therapy*; D012219:Rheumatology / Q000592:standards*
D018501:Antirheumatic Agents